UChicago Annual Updates from ASH 2019
BCL2 Inhibition in Myeloid Malignancies: Venetoclax + Azacitidine in AML and MDS & Navitoclax and Ruxolitinib in Ph-MPNs
By
UChicago Annual Updates from ASH 2019
FEATURING
Olatoyosi Odenike
By
UChicago Annual Updates from ASH 2019
FEATURING
Olatoyosi Odenike
Login to view comments.
Click here to Login